CovidChloroV1, Main, Curation, bibRecord, 001307

SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.

Identifieur interne : 001307 ( Main/Curation ); précédent : 001306; suivant : 001308

SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.

Auteurs : Lin Wu [République populaire de Chine] ; Aislinn M. O'Kane [États-Unis] ; Hu Peng [République populaire de Chine] ; Yaguang Bi [République populaire de Chine] ; Dagmara Motriuk-Smith [États-Unis] ; Jun Ren [États-Unis]

Source :

Biochemical pharmacology [ 1873-2968 ] ; 2020.

RBID : pubmed:32579957

Descripteurs français

KwdFr :
- Antipaludiques (pharmacologie), Antipaludiques (usage thérapeutique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (physiologie), Chloroquine (pharmacologie), Chloroquine (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (pharmacologie), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (complications), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique), Maladies cardiovasculaires (complications), Maladies cardiovasculaires (métabolisme), Maladies cardiovasculaires (traitement médicamenteux), Pandémies (MeSH), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (complications), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Pénétration virale (effets des médicaments et des substances chimiques).
MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus, Pénétration virale.
- métabolisme : Infections à coronavirus, Maladies cardiovasculaires, Peptidyl-Dipeptidase A, Pneumopathie virale.
- pharmacologie : Antipaludiques, Antiviraux, Chloroquine, Hydroxychloroquine, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- physiologie : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- usage thérapeutique : Antipaludiques, Antiviraux, Chloroquine, Hydroxychloroquine, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Pandémies.

English descriptors

KwdEn :
- Angiotensin-Converting Enzyme 2 (MeSH), Angiotensin-Converting Enzyme Inhibitors (pharmacology), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Antimalarials (pharmacology), Antimalarials (therapeutic use), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (physiology), COVID-19 (MeSH), Cardiovascular Diseases (complications), Cardiovascular Diseases (drug therapy), Cardiovascular Diseases (metabolism), Chloroquine (pharmacology), Chloroquine (therapeutic use), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Humans (MeSH), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (virology), SARS-CoV-2 (MeSH), Virus Internalization (drug effects).
MESH :
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , pharmacology : Angiotensin-Converting Enzyme Inhibitors, Antimalarials, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , therapeutic use : Angiotensin-Converting Enzyme Inhibitors, Antimalarials, Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical : Angiotensin-Converting Enzyme 2.
- complications : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus, Virus Internalization.
- drug therapy : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- metabolism : Cardiovascular Diseases.
- physiology : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Humans, Pandemics, SARS-CoV-2.

Abstract

The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mortality. Up-to-date, a number of mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this context, special attention should be given towards COVID-19 patients with concurrent cardiovascular diseases, and special cardiovascular attention is warranted for treatment of COVID-19.

DOI: 10.1016/j.bcp.2020.114114
PubMed: 32579957
PubMed Central: PMC7306106

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001307

Links to Exploration step

pubmed:32579957

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.</title>
<author><name sortKey="Wu, Lin" sort="Wu, Lin" uniqKey="Wu L" first="Lin" last="Wu">Lin Wu</name>
<affiliation wicri:level="1"><nlm:affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="O Kane, Aislinn M" sort="O Kane, Aislinn M" uniqKey="O Kane A" first="Aislinn M" last="O'Kane">Aislinn M. O'Kane</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Wyoming</region>
</placeName>
<wicri:cityArea>School of Pharmacy, University of Wyoming College of Health Sciences, Laramie</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Peng, Hu" sort="Peng, Hu" uniqKey="Peng H" first="Hu" last="Peng">Hu Peng</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Emergency, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Emergency, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bi, Yaguang" sort="Bi, Yaguang" uniqKey="Bi Y" first="Yaguang" last="Bi">Yaguang Bi</name>
<affiliation wicri:level="1"><nlm:affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Motriuk Smith, Dagmara" sort="Motriuk Smith, Dagmara" uniqKey="Motriuk Smith D" first="Dagmara" last="Motriuk-Smith">Dagmara Motriuk-Smith</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Wyoming at Casper and the Department of Zoology and Physiology, Casper, WY 82601, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Wyoming at Casper and the Department of Zoology and Physiology, Casper, WY 82601</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ren, Jun" sort="Ren, Jun" uniqKey="Ren J" first="Jun" last="Ren">Jun Ren</name>
<affiliation wicri:level="1"><nlm:affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China; School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA; Department of Pathology, University of Washington Seattle, Seattle, WA, USA. Electronic address: ren.jun@zs-hospital.sh.cn.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China; School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA; Department of Pathology, University of Washington Seattle, Seattle, WA</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32579957</idno>
<idno type="pmid">32579957</idno>
<idno type="doi">10.1016/j.bcp.2020.114114</idno>
<idno type="pmc">PMC7306106</idno>
<idno type="wicri:Area/Main/Corpus">001307</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001307</idno>
<idno type="wicri:Area/Main/Curation">001307</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001307</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.</title>
<author><name sortKey="Wu, Lin" sort="Wu, Lin" uniqKey="Wu L" first="Lin" last="Wu">Lin Wu</name>
<affiliation wicri:level="1"><nlm:affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="O Kane, Aislinn M" sort="O Kane, Aislinn M" uniqKey="O Kane A" first="Aislinn M" last="O'Kane">Aislinn M. O'Kane</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Wyoming</region>
</placeName>
<wicri:cityArea>School of Pharmacy, University of Wyoming College of Health Sciences, Laramie</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Peng, Hu" sort="Peng, Hu" uniqKey="Peng H" first="Hu" last="Peng">Hu Peng</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Emergency, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Emergency, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bi, Yaguang" sort="Bi, Yaguang" uniqKey="Bi Y" first="Yaguang" last="Bi">Yaguang Bi</name>
<affiliation wicri:level="1"><nlm:affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Motriuk Smith, Dagmara" sort="Motriuk Smith, Dagmara" uniqKey="Motriuk Smith D" first="Dagmara" last="Motriuk-Smith">Dagmara Motriuk-Smith</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Wyoming at Casper and the Department of Zoology and Physiology, Casper, WY 82601, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Wyoming at Casper and the Department of Zoology and Physiology, Casper, WY 82601</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ren, Jun" sort="Ren, Jun" uniqKey="Ren J" first="Jun" last="Ren">Jun Ren</name>
<affiliation wicri:level="1"><nlm:affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China; School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA; Department of Pathology, University of Washington Seattle, Seattle, WA, USA. Electronic address: ren.jun@zs-hospital.sh.cn.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China; School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA; Department of Pathology, University of Washington Seattle, Seattle, WA</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Biochemical pharmacology</title>
<idno type="eISSN">1873-2968</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin-Converting Enzyme 2 (MeSH)</term>
<term>Angiotensin-Converting Enzyme Inhibitors (pharmacology)</term>
<term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term>
<term>Antimalarials (pharmacology)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (physiology)</term>
<term>COVID-19 (MeSH)</term>
<term>Cardiovascular Diseases (complications)</term>
<term>Cardiovascular Diseases (drug therapy)</term>
<term>Cardiovascular Diseases (metabolism)</term>
<term>Chloroquine (pharmacology)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (pharmacology)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Peptidyl-Dipeptidase A (metabolism)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Virus Internalization (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antipaludiques (pharmacologie)</term>
<term>Antipaludiques (usage thérapeutique)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (physiologie)</term>
<term>Chloroquine (pharmacologie)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (pharmacologie)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie)</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term>
<term>Maladies cardiovasculaires (complications)</term>
<term>Maladies cardiovasculaires (métabolisme)</term>
<term>Maladies cardiovasculaires (traitement médicamenteux)</term>
<term>Pandémies (MeSH)</term>
<term>Peptidyl-Dipeptidase A (métabolisme)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pénétration virale (effets des médicaments et des substances chimiques)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors</term>
<term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors</term>
<term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Angiotensin-Converting Enzyme 2</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cardiovascular Diseases</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Virus Internalization</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cardiovascular Diseases</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
<term>Pénétration virale</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cardiovascular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Maladies cardiovasculaires</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Maladies cardiovasculaires</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mortality. Up-to-date, a number of mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this context, special attention should be given towards COVID-19 patients with concurrent cardiovascular diseases, and special cardiovascular attention is warranted for treatment of COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32579957</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2968</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>178</Volume>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>Biochemical pharmacology</Title>
<ISOAbbreviation>Biochem Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.</ArticleTitle>
<Pagination><MedlinePgn>114114</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0006-2952(20)30350-6</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2020.114114</ELocationID>
<Abstract><AbstractText>The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mortality. Up-to-date, a number of mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this context, special attention should be given towards COVID-19 patients with concurrent cardiovascular diseases, and special cardiovascular attention is warranted for treatment of COVID-19.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Lin</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>O'Kane</LastName>
<ForeName>Aislinn M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peng</LastName>
<ForeName>Hu</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Emergency, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bi</LastName>
<ForeName>Yaguang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Motriuk-Smith</LastName>
<ForeName>Dagmara</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>University of Wyoming at Casper and the Department of Zoology and Physiology, Casper, WY 82601, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ren</LastName>
<ForeName>Jun</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai 200032, China; School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071 USA; Department of Pathology, University of Washington Seattle, Seattle, WA, USA. Electronic address: ren.jun@zs-hospital.sh.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Biochem Pharmacol</MedlineTA>
<NlmUniqueID>0101032</NlmUniqueID>
<ISSNLinking>0006-2952</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ACE2</Keyword>
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Cardiovascular</Keyword>
<Keyword MajorTopicYN="Y">Cytokine storm</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32579957</ArticleId>
<ArticleId IdType="pii">S0006-2952(20)30350-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.bcp.2020.114114</ArticleId>
<ArticleId IdType="pmc">PMC7306106</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Postgrad Med J. 2006 Feb;82(964):140-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16461478</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Rev Allergy Immunol. 2012 Apr;42(2):145-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21221847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2016 Aug;49:129-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27352628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 2011 Oct;31(10):705-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21861699</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Allergy. 2020 Jul;75(7):1730-1741</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):819-824</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219357</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):419-423</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30948970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):706-712</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101647</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32247927</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2020 Mar 16;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32176300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 Apr;93:201-204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32097725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2015 Jan 20;313(3):264-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25602997</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Lett. 2010 Nov 30;199(2):173-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20837116</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Ther. 2020;14(1):58-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 Jul;96:348-351</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32389847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jul;92(7):740-746</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227493</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 21;323(15):1499-1500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32159735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):811-818</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219356</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 2;395(10234):1417-1418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32325026</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 29;395(10225):683-684</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32122468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 26;323(20):2052-2059</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1612-1614</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2020 May 14;41(19):1858</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Apr;80(4):388-393</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32112884</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Res Cardiol. 2020 May;109(5):531-538</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32161990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AJP Rep. 2020 Apr;10(2):e165-e168</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32509415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Apr;18(4):844-847</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32073213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respirology. 2018 Feb;23(2):130-137</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29052924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32164080</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO Mol Med. 2010 Jul;2(7):247-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20597104</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 1999 Apr 27;99(16):2192-217</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10217662</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2002 Jun 20;417(6891):822-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12075344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 Apr;46(4):586-590</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Heart Fail Rev. 2017 Nov;22(6):889-902</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28762019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2017 Sep 7;21(1):234</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28877748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 29;395(10225):689-697</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32014114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 1997 Sep;30(3 Pt 2):535-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9322978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2020 Jul;158(1):e9-e13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32243945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiology. 2007;107(2):73-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16804295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Soc Nephrol. 2006 Nov;17(11):2985-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17035613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Saudi Med. 2016 Jan-Feb;36(1):78-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26922692</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Invest. 2009 Jul;39(7):618-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19453650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2020 May 26;141(21):1665-1666</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32242749</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 2013 Sep;76(3):455-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23305158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 2016 Apr;129(4):446.e5-446.e21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26593739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2020 May 1;130(5):2202-2205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):825-830</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32324209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2017 Aug 22;7(1):9110</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28831119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22390970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chembiochem. 2020 Mar 2;21(5):730-738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32022370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EXCLI J. 2017 Jul 21;16:1057-1072</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28900385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):473-475</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32043983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32311448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Heart Fail. 2020 May;22(5):911-915</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Dev Res. 2020 Aug;81(5):537-540</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32129518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Resuscitation. 2020 Jun;151:18-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283117</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2007 Jan;54(1):28-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16542729</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Inflam. 2014;2014:689360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24804145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Immunol. 2004 Apr;136(1):95-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030519</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Pharmacol Sci. 2004 Jun;25(6):291-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15165741</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2020 Jun 5;126(12):1671-1681</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2020 Jul 14;142(2):184-186</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32242738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2003 Oct 7;108(14):1707-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14504186</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chin Med J (Engl). 2020 May 5;133(9):1025-1031</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32044814</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001307 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001307 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32579957
   |texte=   SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:32579957" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.

SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki